Article | Published:

Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model


Defects in the phosphoinositide 3-kinase (PI3K) pathway are shared characteristics in several brain disorders, including the inherited intellectual disability and autism spectrum disorder, fragile X syndrome (FXS). PI3K signaling therefore could serve as a therapeutic target for FXS and other brain disorders. However, broad inhibition of such a central signal transduction pathway involved in essential cellular functions may produce deleterious side effects. Pharmacological strategies that selectively correct the overactive components of the PI3K pathway while leaving other parts of the pathway intact may overcome these challenges. Here, we provide the first evidence that disease mechanism-based PI3K isoform-specific inhibition may be a viable treatment option for FXS. FXS is caused by loss of the fragile X mental retardation protein (FMRP), which translationally represses specific messenger RNAs, including the PI3K catalytic isoform p110β. FMRP deficiency increases p110β protein levels and activity in FXS mouse models and in cells from subjects with FXS. Here, we show that a novel, brain-permeable p110β-specific inhibitor, GSK2702926A, ameliorates FXS-associated phenotypes on molecular, cellular, behavioral, and cognitive levels in two different FMRP-deficient mouse models. Rescued phenotypes included increased PI3K downstream signaling, protein synthesis rates, and dendritic spine density, as well as impaired social interaction and higher-order cognition. Several p110β-selective inhibitors, for example, a molecule from the same chemotype as GSK2702926A, are currently being evaluated in clinical trials to treat cancer. Our results suggest that repurposing p110β inhibitors to treat cognitive and behavioral defects may be a promising disease-modifying strategy for FXS and other brain disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol. 2016;12:379–92.

  2. 2.

    Lipton Jonathan O, Sahin M. The neurology of mTOR. Neuron. 2014;84:275–91.

  3. 3.

    Gross C, Hoffmann A, Bassell GJ, Berry-Kravis EM. Therapeutic strategies in fragile X syndrome: from bench to bedside and back. Neurotherapeutics. 2015;12:584–608.

  4. 4.

    Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nat Rev Neurosci. 2015;16:595–605.

  5. 5.

    Qin M, Kang J, Smith CB. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA. 2002;99:15758–63.

  6. 6.

    Weiler IJ, Spangler CC, Klintsova AY, Grossman AW, Kim SH, Bertaina-Anglade V, et al. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci USA. 2004;101:17504–9.

  7. 7.

    Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci. 2007;27:5338–48.

  8. 8.

    Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of Fragile X mental retardation. Proc Natl Acad Sci USA. 2002;99:7746–50.

  9. 9.

    Bear MF, Huber KM, Warren ST. The mGluR theory of Fragile X mental retardation. Trends Neurosci. 2004;27:370–7.

  10. 10.

    Scharf SH, Jaeschke G, Wettstein JG, Lindemann L. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr Opin Pharmacol. 2015;20C:124–34.

  11. 11.

    Berry-Kravis E, Des Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak J, et al. Mavoglurant in Fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med. 2016;8:321ra325–321ra325.

  12. 12.

    Bhattacharya A, Mamcarz M, Mullins C, Choudhury A, Boyle RG, Smith DG, et al. Targeting translation control with p70 S6 kinase 1 inhibitors to reverse phenotypes in Fragile X syndrome mice. Neuropsychopharmacology. 2016;41:1991–2000.

  13. 13.

    Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R, et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med. 2017;23:674–7.

  14. 14.

    Brown V, Jin P, Ceman S, Darnell JC, O’Donnell WT, Tenenbaum SA, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107:477–87.

  15. 15.

    Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247–61.

  16. 16.

    Ascano M Jr., Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature. 2012;492:382–6.

  17. 17.

    Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003;37:417–31.

  18. 18.

    Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci. 2010;30:10624–38.

  19. 19.

    Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, et al. Dysregulation of mTOR signaling in Fragile X syndrome. J Neurosci. 2010;30:694–702.

  20. 20.

    Gross C, Raj N, Molinaro G, Allen AG, Whyte AJ, Gibson JR, et al. Selective role of the catalytic PI3K subunit p110beta in impaired higher order cognition in Fragile X syndrome. Cell Rep. 2015;11:681–8.

  21. 21.

    Dbouk HA, Backer JM. A beta version of life: p110β takes center stage. Oncotarget. 2010;1:729–33.

  22. 22.

    Li B, Sun A, Jiang W, Thrasher JB, Terranova P. PI-3 kinase p110β: a therapeutic target in advanced prostate cancers. Am J Clin Exp Urol. 2014;2:188–98.

  23. 23.

    Rivero RA, Tedesco R, Luengo JI. Benzimidazole boronic acid derivatives as PI3 kinase inhibitors. Google patents, 2014.

  24. 24.

    Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron. 2012;76:325–37.

  25. 25.

    Deacon RM. Assessing nest building in mice. Nat Protoc. 2006;1:1117–9.

  26. 26.

    Thomas AM, Bui N, Graham D, Perkins JR, Yuva-Paylor LA, Paylor R. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. Behav Brain Res. 2011;223:310–21.

  27. 27.

    Banerjee A, Luong JA, Ho A, Saib AO, Ploski JE. Overexpression of Homer1a in the basal and lateral amygdala impairs fear conditioning and induces an autism-like social impairment. Mol Autism. 2016;7:16.

  28. 28.

    Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci. 2010;11:490–502.

  29. 29.

    Lin H, Erhard K, Hardwicke MA, Luengo JI, Mack JF, McSurdy-Freed J, et al. Synthesis and structure–activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorg Med Chem Lett. 2012;22:2230–4.

  30. 30.

    Murakami H, Takanaga H, Matsuo H, Ohtani H, Sawada Y. Comparison of blood–brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol Heart Circ Physiol. 2000;279:H1022–28.

  31. 31.

    Dwivedi Y, Rizavi HS, Teppen T, Zhang H, Mondal A, Roberts RC, et al. Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects. Neuropsychopharmacology. 2008;33:2324–40.

  32. 32.

    Biever A, Valjent E, Puighermanal E. Ribosomal protein S6 phosphorylation in the nervous system: from regulation to function. Front Mol Neurosci. 2015;8:75.

  33. 33.

    Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, et al. S6K1(−/−)/S6K2(−/−) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol. 2004;24:3112–24.

  34. 34.

    Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009;6:275–7.

  35. 35.

    Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, Bauchwitz RP. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav. 2004;3:337–59.

  36. 36.

    Kazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res. 2014;3:118–33.

  37. 37.

    Udagawa T, Farny NG, Jakovcevski M, Kaphzan H, Alarcon JM, Anilkumar S, et al. Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nat Med. 2013;19:1473–7.

  38. 38.

    Gross C, Bassell GJ. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol Med. 2012;18:336–45.

  39. 39.

    Park S, Park JM, Kim S, Kim JA, Shepherd JD, Smith-Hicks CL, et al. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron. 2008;59:70–83.

  40. 40.

    Guo W, Ceolin L, Collins KA, Perroy J, Huber KM. Elevated CaMKIIalpha and hyperphosphorylation of homer mediate circuit dysfunction in a fragile X syndrome mouse model. Cell Rep. 2015;13:2297–311.

  41. 41.

    Ronesi JA, Collins KA, Hays SA, Tsai NP, Guo W, Birnbaum SG, et al. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat Neurosci. 2012;15:431–40. S431

  42. 42.

    Huang GN, Huso DL, Bouyain S, Tu J, McCorkell KA, May MJ, et al. NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science. 2008;319:476–81.

  43. 43.

    Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329–41.

  44. 44.

    Smith GC, Ong WK, Costa JL, Watson M, Cornish J, Grey A, et al. Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength. FEBS J. 2013;280:5337–49.

  45. 45.

    Law AJ, Wang Y, Sei Y, O’Donnell P, Piantadosi P, Papaleo F, et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy. Proc Natl Acad Sci USA. 2012;109:12165–70.

  46. 46.

    Kim JI, Lee HR, Sim SE, Baek J, Yu NK, Choi JH, et al. PI3Kgamma is required for NMDA receptor-dependent long-term depression and behavioral flexibility. Nat Neurosci. 2011;14:1447–54.

  47. 47.

    Papaleo F, Yang F, Paterson C, Palumbo S, Carr GV, Wang Y, et al. Behavioral, Neurophysiological, and synaptic impairment in a transgenic neuregulin1 (NRG1-IV) murine schizophrenia model. J Neurosci. 2016;36:4859–75.

  48. 48.

    Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105:1607–16.

  49. 49.

    Davis PE, Peters JM, Krueger DA, Sahin M. Tuberous sclerosis: a new frontier in targeted treatment of autism. Neurotherapeutics. 2015;12:572–83.

  50. 50.

    Crawley JN, Heyer W-D, LaSalle JM. Autism and cancer share risk genes, pathways, and drug targets. Trends Genet. 2016;32:139–46.

Download references


We thank Jeffrey Rymer, Nathan Petts, Joun Y. Lee, and Jingsheng Gu for technical assistance, and Emanuela Santini as well as all members of the Bassell, Gourley, and Gross labs for helpful discussions. This research was funded by NIH grants R21MH103748 (to C.G., S.L.G.) and 1U54HD082013 (to G.J.B.), a NARSAD Independent Investigator Award from the Brain and Behavior Research Foundation (to C.G.), two Summer Student Fellowships from the National Fragile X Foundation (to J.C.K., N.A.E.), the Cincinnati Children’s Research Foundation (to C.G.), and Children’s Healthcare of Atlanta (to S.L.G.). The Yerkes National Primate Research Center is supported by the Office of Research Infrastructure Programs/OD P51OD011132.

Author information

Competing interests

GSK6A was obtained through a Material Transfer Agreement from GlaxoSmithKline. R.A.R. is an employee of GlaxoSmithKline, who owns GSK6A, and is co-inventor on US patents US 20130157977A1 and US 8778937B2. C.G. and G.J.B. are co-inventors on provisional patent application 62/680,050. All other authors declare no competing interests.

Correspondence to Christina Gross or Shannon L. Gourley.

Electronic supplementary material

Supplementary Information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5